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ABSTRACTϮϲ
Ϯϳ
Objective: Endometrial cancer primarily affects elderly women. The aim of the present Ϯϴ
literature review is to define the population of elderly women with this disease and to define Ϯϵ
the characteristics of this cancer in elderly people as well as its surgical treatment. ϯϬ
Materials and Methods: A systematic review of the English-language literature of the last 20 ϯϭ
years indexed in the PubMed database. ϯϮ
Results: Endometrial cancer is more aggressive in elderly women. However, surgical staging ϯϯ
performed in elderly patients is often not concomitant with the disease’s aggressiveness in this ϯϰ
group. Mini-invasive surgery is performed less often, for no obvious reason. Of note, ϯϱ
oncogeriatric evaluation was not usually ruled out to determine the most appropriate surgical ϯϲ
modality.  ϯϳ
Conclusion: Studies are needed to evaluate surgical management of endometrial cancer in ϯϴ
elderly women, notably with the aid of oncogeriatric scores to predict surgical morbidity.  ϯϵ
ϰϬ
ϰϭ
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ϰϯ
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INTRODUCTION ϰϳ
ϰϴ
Endometrial cancer is a disease primarily affecting elderly women: the mean age at ϰϵ
diagnosis is 68 years (1). The current population is getting older, so the incidence of the ϱϬ
disease and also its management are set to increase in the coming years. Anyone who takes an ϱϭ
interest in this disease in the specific subpopulation formed by elderly women will notice it ϱϮ
has features specific to this age group. The aim of the present literature review is to define ϱϯ
which kind of endometrial cancer was found in elderly, how to define elderly and to focus on ϱϰ
the surgical management performed and complications in elderly. In addition, we describe the ϱϱ
feasibility and value of managing the disease in this age group using a mini-invasive approach ϱϲ
(laparoscopic or robotic). ϱϳ
ϱϴ
ϱϵ
ϲϬ
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MATERIALS AND METHODS ϲϭ
Inclusion criteria were studies that included adult femals with either age more than 65 years ϲϮ
old and endometrial cancer with surgery. Exclusion criteria were patients with recurrent ϲϯ
endometrial cancer, studies with no inclusion of women older than 65 years, duplicate data.  ϲϰ
Because of lack consensus of elderly woman definition in literature, authors researched also ϲϱ
geriatric tools in order to define frailty. Inclusion criteria for this search were “oncologic ϲϲ
score”.   ϲϳ
The primary outcomes were rate of post-operative complications (morbidity and mortality), ϲϴ
histo-pathological analysis of uterus and nodes and survival rate. The secondary outcome was ϲϵ
described oncogeriatric scores nevertheless kind of cancer.   ϳϬ
Original studies, meta-analyses and reviews published in English and French were ϳϭ
considered. In case of duplicate publications from the same team, the most recent study was ϳϮ
included. Case reports were excluded. Two investigators (CB and VL) independently ϳϯ
extracted the data from the remaining studies. Finally, all the authors scrutinized relevant ϳϰ
studies and a decision made on their inclusion in the review.  ϳϱ
The bibliographic search was carried out for the period covering the last 20 years (January, ϳϲ
1995 to January, 2015). The following sources were explored:  ϳϳ
- Medline: PubMed (the Internet portal of the National Library of Medicine) ϳϴ
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed ϳϵ
- Central Cochrane Library ϴϬ
- EmBase ϴϭ
- National Institute on Aging ϴϮ
http://www.nia.nih.govͬsites/default/files/ ϴϯ
- INSEE: Institut National des Statistiques et des Etudes Economiquesϴϰ
http://www.insee.fr/fr/themes/document ϴϱ
The authors used various key words, alone or in combination, to produce maximum results ϴϲ
during the literature search. The following key words were used: elderly women, older, ϴϳ
frailty, laparoscopy, laparotomy, vaginal hysterectomy, surgery, recidive, specific survival, ϴϴ
morbidity, endometrial carcinoma, endometrial cancer, oncogeriatric score. To minimize the ϴϵ
possibility of duplication, all key fields of a particular study were downloaded including ϵϬ
unique identifier (e.g. PMID), digital object identifier (DOI), clinical trial number (from ϵϭ
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www.clinicaltrials.gov), abstract and key words. The initial citations were then merged into ϵϮ
one file using the Endnote software and duplicate results were removed. The title of each ϵϯ
study was individually reviewed by designated authors to identify the studies addressing the ϵϰ
research question. Thereafter, abstracts of selected studies were reviewed according to the ϵϱ
predefined inclusion and exclusion criteria and irrelevant studies were removed. Studies ϵϲ
meeting all inclusion and exclusion criteria were selected for full-text review and data ϵϳ
extraction. ϵϴ
ϵϵ
ϭϬϬ
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RESULTS ϭϬϭ
ϭϬϮ
The electronic database literature search identified 25635 articles on endometrial ϭϬϯ
cancer of which 2117 were about surgical staging and only 16 with detailed data about ϭϬϰ
women older than 65 years old.  Authors identified only two studies that assessed ϭϬϱ
oncogeriatric score for surgery, of which only one deled with gynecologic oncology (2)(3).  ϭϬϲ
There is a lack of consensus in the definition of elderly and consequently there is a high ϭϬϳ
heterogeneity of the published data to clearly review the subject.  ϭϬϴ
ϭϬϵ
What is an elderly woman? ϭϭϬ
ϭϭϭ
 In order to optimise the surgical management of elderly patients, it is important to ϭϭϮ
better define what an elderly patient is, especially in surgery, and notably which of these ϭϭϯ
elderly patients are at risk of complications. ϭϭϰ
There is no consensus in the current literature as regards the definition of “elderly woman”, ϭϭϱ
variously described as being over 63, 65, 70 or 75 years. Defining what constitutes an old ϭϭϲ
person is a complex issue. One of the commonly used criteria is age, with the threshold age ϭϭϳ
set at 65 years by the WHO (4) and the INSEE (5), and 75 years by the InCA (Institut ϭϭϴ
National du Cancer). Another criterion, more socioeconomic, is to consider elderly as people ϭϭϵ
who are no longer working. Hence, age is not a good way of predicting postoperative ϭϮϬ
complications. Although not as straightforward to apply as age, vulnerability, frailty and ϭϮϭ
dependence are better able to detect people to manage geriatrically and who are at risk of ϭϮϮ
complications. Hence old age is not defined in relation to a specific age but rather as a state of ϭϮϯ
functional incapacity, whether subjective or objective. The concept of frailty, today adopted ϭϮϰ
by geriatricians, corresponds to a reduction in physiological reserves limiting the patient’s ϭϮϱ
capacity to respond to a stress and predisposing him/her to adverse events. It corresponds to a ϭϮϲ
phenotype found in patients living in an institution, who have an excess risk of falls, ϭϮϳ
hospitalisation, or other adverse events (6). As mentioned above, the population is getting ϭϮϴ
older and life expectancy is increasing considerably. According to the INSEE, the life ϭϮϵ
expectancy at 65 years for a woman is currently 23 years, while expectancy of life in “good ϭϯϬ
health” at 65 years is 9 years (7). In relation to the topic we are interested in, surgery, the ϭϯϭ
notion of good health is a very important one. ϭϯϮ
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Even though a definition of elderly in the field of surgery is lacking, it will be accepted ϭϯϯ
that such a person has fewer physiological reserves to respond to the stress of a surgical ϭϯϰ
procedure (anaesthesia, perioperative bleeding) or postoperative complications. So, in elderly ϭϯϱ
people, more important than the rate of complications is that when a complication occurs ϭϯϲ
postoperatively, it is less well tolerated and causes a chain reaction of other complications. ϭϯϳ
Furthermore, elderly people may present complications specific to their age (e.g. confusion, ϭϯϴ
falls, etc.), while so-called “classic” postoperative complications may have atypical ϭϯϵ
presentations that the physician must be able to diagnose (8). In this context, new ϭϰϬ
oncogeriatric scores are being used to better detect elderly people at risk of complications and ϭϰϭ
those who would benefit from optimal medicosurgical treatment. ϭϰϮ
ϭϰϯ
Oncogeriatric scores ϭϰϰ
ϭϰϱ
 The goal is to perform a comprehensive geriatric assessment (CGA), encompassing ϭϰϲ
the somatic, functional and psychosocial domains, to provide an objective evaluation of the ϭϰϳ
health status of the elderly person, so that a multidisciplinary care plan may be devised. The ϭϰϴ
CGA uses several scores such as the MNA (Mini Nutritional Assessment), the ADL (Activity ϭϰϵ
of Daily Living) and IADL (Instrumental Activity of Daily Living) that evaluate dependence, ϭϱϬ
the MMSE (Mini Mental State Examination), the CIRS-G (Cumulative Illness Rating Scale ϭϱϭ
for Geriatrics) evaluating comorbidities (9). The “timed get up and go test” (TUG) evaluates ϭϱϮ
the risk of a fall, the VES-13 (Vulnerable Elders Scale) evaluates survival and decline and the ϭϱϯ
GDS (Geriatric Depression Scale) evaluates depressive symptoms. A literature review ϭϱϰ
involving 51 publications showed that frailty, nutritional status and comorbidities are ϭϱϱ
predictive of all-cause mortality. Frailty is predictive of chemotherapy toxicity; cognitive ϭϱϲ
impairment and a reduction in the ADL are predictive of chemotherapy discontinuation; ϭϱϳ
reduction in the IADL is predictive of perioperative complications (10). The authors of the ϭϱϴ
review express their reservations as to the validity of these tests, given that the studies are too ϭϱϵ
heterogeneous to guide clinical decisions. Regardless of the issue of heterogeneity, the ϭϲϬ
reference oncogeriatric evaluation test, the MGA (Multidimensional Geriatric Assessment), ϭϲϭ
consisting of 7 items (MNA, TUG, ADL, IADL, MMSE, GDS and CIRS-G), takes a long ϭϲϮ
time to administer, such that, despite the recommendations of the International Society of ϭϲϯ
Geriatric Oncology (SIOG), level of use is very low. Currently, the scientific community ϭϲϰ
believes that for a test to be acceptable, it must take about 10 minutes of the practitioner’s ϭϲϱ
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time. With this in mind, the G8 tool was developed to identify patients who should undergo a ϭϲϲ
geriatric evaluation. G8 consists of 8 items and its validity was recently assessed in a large, ϭϲϳ
multicentre study (ONCODAGE), which showed that it takes an average of 5 minutes to ϭϲϴ
complete it, it is more sensitive than VES-13 (p=0.004) and that an abnormal score (≤ 14/17) ϭϲϵ
is predictive of 1-year survival (p=0.0001). At the present time, G8 seems to be one of the ϭϳϬ
best tools for detecting elderly patients who should undergo a geriatric evaluation (11). The ϭϳϭ
current literature does not provide a specific score to evaluate perioperative risks in elderly ϭϳϮ
people with cancer. Possibly because they are under-represented in clinical trials (12) (13), ϭϳϯ
making their management even more difficult. Nevertheless, some studies have used existing ϭϳϰ
oncogeriatric scores to evaluate this risk. Among these, a prospective study by the SIOG ϭϳϱ
evaluated an extension of the CGA, the PACE (Preoperative Assessment in Elderly Cancer ϭϳϲ
Patients), for its ability to assess the suitability of elderly cancer patients for surgery. This ϭϳϳ
study used the MMS, ADL, IADL, GDS, BFI (Brief Fatigue Inventory), ECOG performance ϭϳϴ
status (PS), ASA (American Society of Anesthesiology) scale and SIC (Satariano’s Index of ϭϳϵ
Comorbidities). Results showed that the IADL, fatigue and PS were associated with a 50% ϭϴϬ
increase in the relative risk of postoperative complications (p<0.05). On multivariate analysis, ϭϴϭ
this study identified moderate to severe fatigue, the IADL and the PS as factors predictive of ϭϴϮ
postoperative complications (p<0.05). Finally, deterioration of IADL and PS were associated ϭϴϯ
with a longer hospital stay (p<0.05) (14). Independently of oncogeriatric scores but ϭϴϰ
specifically in oncogynaecology, a retrospective Italian study evaluated perioperative ϭϴϱ
morbidity and mortality in patients aged over 70 years as a function of the ASA score. It ϭϴϲ
found a higher rate of postoperative complications in ASA III/IV patients than in ASA I/II ϭϴϳ
patients (p ≤ 0.001) (15). There is no consensus regarding the definition of frailty. However ϭϴϴ
Makary et al. established a frailty scale based on 5 criteria: weakness, weight loss, exhaustion, ϭϴϵ
low physical activity and slow walking speed. This scale was tested in a prospective surgical ϭϵϬ
study and was found to predict postoperative complications, length of hospital stay and ϭϵϭ
placement in an institution of elderly people (2). In the specific domain of gynaecological ϭϵϮ
surgical oncology, it has been established that preoperative frailty in elderly women is ϭϵϯ
predictive of postoperative morbidity (postoperative complications and rehospitalisation ϭϵϰ
within 30 days) (3). The score uses 5 variables that were previously validated by Fried et al.ϭϵϱ
as defining frailty (6): weight loss, reduction in grip strength, exhaustion, low physical ϭϵϲ
activity and slowing of walking speed. Each variable is rated as 0 or 1. According to the ϭϵϳ
frailty index, patients are classified as non-frail (0–1), intermediate-frail (2–3) or frail (4–5). ϭϵϴ
Although this scale performs better than usual scores (ASA, ECOG, Charlson Comorbidity ϭϵϵ
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Index) (2) (16), it is still too time-consuming (approximately 20 min). As the only existing ϮϬϬ
tool for evaluating frailty in elderly women in the specific field of gynaecological oncological ϮϬϭ
surgery, other studies are necessary in order to improve it and make it more practical.  ϮϬϮ
ϮϬϯ
Characteristics of endometrial cancer in elderly women ϮϬϰ
ϮϬϱ
Epidemiology ϮϬϲ
ϮϬϳ
In terms of incidence, endometrial cancer ranks number 4 among women, with 7,200 ϮϬϴ
new cases per year in 2012 in France (InVS: Institut National de Veille Sanitaire) and it is the ϮϬϵ
5th most common cause of cancer mortality in women. It primarily occurs after the ϮϭϬ
menopause, with a mean age of 68 years at diagnosis. The relative 5-year survival rate is 76% Ϯϭϭ
overall, increasing to 95% for localised early stages. With the aging of population, a ϮϭϮ
concomitant increase in the incidence of endometrial cancer can be observed: the probability Ϯϭϯ
of developing endometrial cancer at ages 40–59 is 0.77%, rising to 0.87% at ages 60–69 and Ϯϭϰ
1.24% at age > 70 years (17). Hence, as women get older, they have a higher risk of Ϯϭϱ
developing endometrial cancer. It is interesting to know the National Institute on Ϯϭϲ
Aging estimates that in 2050 there will be 150 million people aged at least 65 years, Ϯϭϳ
representing 16% of the world population. Women will make up an increasing share of the Ϯϭϴ
population. People aged over 85 years (“the oldest old”) represent 8% of the population aged Ϯϭϵ
over 65 years and up to 12% in more developed countries (4). The European Union has the ϮϮϬ
highest percentage of people aged over 65 in the world: currently around 20% and forecast to ϮϮϭ
increase to 30% in 2060 (5). In line with aging of the female population, the incidence of ϮϮϮ
endometrial cancer will increase. In this context, it seems useful to better characterise this ϮϮϯ
disease in the specific population of elderly women.  ϮϮϰ
ϮϮϱ
A more aggressive cancer ϮϮϲ
ϮϮϳ
Literature data show that endometrial cancer is more aggressive in elderly women, ϮϮϴ
notably in terms of immunohistological profile and stage at which the disease is discovered. A ϮϮϵ
retrospective American study involving 396 patients showed that, compared to younger ϮϯϬ
patients, those aged over 65 years had significantly more of serous and clear cell subtypes Ϯϯϭ
(both histological type 2) associated with a poorer prognosis (18) than the endometrioid ϮϯϮ
subtype (p = 0.004) and also more histological grade 3 tumours (p=0.001). In this study, a Ϯϯϯ
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stratified analysis by 4 age groups showed that patients aged over 75 years had serous Ϯϯϰ
carcinoma more often than patients aged below 45 years (22% vs 5%; p=0.055), and more Ϯϯϱ
grade 3 tumours too (42% vs 16% p=0.001) (19). A more recent study evaluating biological Ϯϯϲ
markers of endometrial cancer aggressiveness, such as mutation of the p53 protein and Ϯϯϳ
decreased expression of the E-Cadherin protein, using 136 pathology slides, showed that Ϯϯϴ
advancing age is directly correlated with tumour stage (r=0.29; p=0.0008) , expression of a Ϯϯϵ
mutated p53 protein (r=0.25; p=0.004) and is inversely correlated with expression of E-ϮϰϬ
Cadherin (r = -0.28; p=0.001) (20). An American study evaluating survival in a cohort of 243 Ϯϰϭ
elderly patients with endometrial cancer demonstrated a significantly higher proportion of ϮϰϮ
serous carcinoma in patients aged over 63 years (28% vs 15%; p=0.002) (21). In parallel, an Ϯϰϯ
Italian study involving a prospective cohort of 108 patients with endometrial cancer and Ϯϰϰ
comparing laparoscopy in women over vs below 65 years found significantly more grade 3 Ϯϰϱ
tumours in the older group (33.3% vs 16.7%; p=0.05) (22). In this study, the tumour Ϯϰϲ
histological types were similar in both groups. A Canadian study comparing the management Ϯϰϳ
of endometrial cancer by robotic surgery in patients aged below 70 years, from 70 to 80 years Ϯϰϴ
and over 80 years found that both FIGO (International Federation of Gynecology and Ϯϰϵ
Obstetrics) stage and histological grade were more advanced in the older group (p=0.023 and ϮϱϬ
p=0.002, respectively) (23). In this study, there were no differences between the 3 age groups Ϯϱϭ
with regard to histological type 1 (endometrioid carcinoma) or 2. Finally, a similar study by ϮϱϮ
Vaknin et al. in 2010 in women aged over versus under 70 years found a higher rate of Ϯϱϯ
advanced FIGO stages (III and IV) in the older group (39% vs 18.7%; p<0.04) (24).  Ϯϱϰ
Hence, endometrial cancers affecting elderly women are more aggressive than those in Ϯϱϱ
younger patients, in terms of histological type (type 2), histological grade or FIGO stage at the Ϯϱϲ
time of diagnosis. The FIGO stage reflects the degree of advancement of the disease and it Ϯϱϳ
correlates directly with 5-year survival (25). The observation that disease is more advanced at Ϯϱϴ
time of diagnosis in elderly patients may be directly due to the fact that their tumours are Ϯϱϵ
inherently more aggressive. Alternatively, it may be due to delays in the management of ϮϲϬ
elderly people or a delay on the part of the elderly person in seeking care, given that 20% of Ϯϲϭ
elderly people wait at least one year before consulting for clearly defined symptoms (26).  ϮϲϮ
Ϯϲϯ
Ϯϲϰ
Ϯϲϱ
Ϯϲϲ
Ϯϲϳ
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Which carcinogenesis? Ϯϲϴ
Ϯϲϵ
The difference in histology has been described for several years and it reflects two ϮϳϬ
different pathways of carcinogenesis. The first, the “classic” pathway, starts with a Ϯϳϭ
hyperplastic precursor or an atypical hyperplastic component that, following oestrogenic ϮϳϮ
stimulation, undergoes malignant transformation into endometrioid adenocarcinoma. These Ϯϳϯ
tumours are more frequent in younger, obese patients and are associated with a less advanced Ϯϳϰ
stage and grade. The other “alternative” pathway starts with an atrophic endometrium without Ϯϳϱ
oestrogenic stimulation and leads to development of serous cancers of the endometrium. This Ϯϳϲ
second type is more frequent in elderly women and is associated with a more advanced stage Ϯϳϳ
and grade, and also with poorer prognosis (27). These pathophysiological hypotheses are Ϯϳϴ
corroborated by literature data showing that BMI (Body Mass Index) is lower in elderly Ϯϳϵ
women with endometrial cancer. Lachance et al. divided their 396 patients into 3 age groups ϮϴϬ
(< 45 years, 46–64 years, > 65 years) and found an inverse relationship between age and BMI Ϯϴϭ
(40.3, 35.3, 31 respectively; p<0.001) (19). In their retrospective study involving 338 patients ϮϴϮ
with endometrial cancer aged over 50 years, Fleming et al. assessed age as a predictor of poor Ϯϴϯ
prognosis and similarly found that patients aged 50–69 had a mean BMI of 31 while those Ϯϴϰ
aged > 70 had a mean BMI of 28 (p=0.004) (28). The previously mentioned Canadian study Ϯϴϱ
in women with endometrial cancer found a mean BMI of 32.8 in patients < 70 years, 30.2 in Ϯϴϲ
those aged 70–80 and 21.5 for those aged > 80 (p=0.0001) (23).  Ϯϴϳ
These morphological data are in favour of a carcinogenesis via the alternative pathway. Ϯϴϴ
Ϯϴϵ
Survival and recurrence ϮϵϬ
Ϯϵϭ
The prognosis of endometrial cancer is grimmer in elderly patients. An American ϮϵϮ
study from 2003 involving 405 patients with stage IB or II (former FIGO classification) Ϯϵϯ
endometrial cancer divided into 2 age groups, older and younger than 70 years, found a higher Ϯϵϰ
rate of recurrence in the older group (12% vs 5%; p=0.03) (29). It also found a lower 5-year Ϯϵϱ
cancer-specific survival rate in the older group (82% vs 95%; p=0.03). On multivariate Ϯϵϲ
analysis, age over 70 years was also a significant factor predictive of poorer survival Ϯϵϳ
(p=0.03). Disease-specific survival was also less good in elderly women on both univariate Ϯϵϴ
and multivariate analysis (p=0.02 and 0.03 respectively). In their cohort of 243 patients, Jolly Ϯϵϵ
et al. (2006) found that the 5-year recurrence rate was higher in patients aged over 63 years ϯϬϬ
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compared to those aged below 63 years (32% vs 15%; p=0.02), and that endometrial cancer-ϯϬϭ
specific survival was worse in the older patients (75% vs 91%; p=0.003) (21). In 2013, an ϯϬϮ
Italian study involving 124 elderly patients with endometrial cancer found that disease-ϯϬϯ
specific survival was lower in those aged over 80 years than in those aged below 80 years ϯϬϰ
(56% vs 83%; p=0.008) (30). Only Fleming et al. did not find a significant difference in ϯϬϱ
recurrence-free survival and disease-specific survival between patients aged over versus ϯϬϲ
below 70 years (28).  ϯϬϳ
Compared to younger patients, elderly patients with endometrial cancer have a higher ϯϬϴ
recurrence rate and higher cancer-specific mortality. ϯϬϵ
One question remains unanswered by the literature: is there a difference in survival between ϯϭϬ
the two age groups when histology is similar? If this is the case, is the (surgical and adjuvant) ϯϭϭ
management of this cancer in elderly women not less optimal? (31) (32). In spite of elderly ϯϭϮ
patients want their cancer to be treated as radically and completely as possible (33), this ϯϭϯ
possible undertreatment could be explained by apprehension among medical practitioners ϯϭϰ
about providing onerous treatments to this frailer patient group.  ϯϭϱ
ϯϭϲ
What surgical management for elderly patients? ϯϭϳ
ϯϭϴ
 Today, management of endometrial cancer is determined by the FIGO classification, ϯϭϵ
which is based on the histology of the tumour, and lymph node involvement, obtained by ϯϮϬ
lymphadenectomy and histopathological analysis. One question concerning elderly women ϯϮϭ
with endometrial cancer is whether they receive optimal surgical management and by which ϯϮϮ
approach: vaginal, laparotomic, or laparoscopic assisted by robot or not? This then leads to ϯϮϯ
the question about the morbidity of surgical management in patients considered to be frailer. ϯϮϰ
The bibliographic search identified 16 trials looking at the issue of surgical management of ϯϮϱ
endometrial cancer in elderly people. Among these trials, 2 looked at the vaginal approach ϯϮϲ
(30) (34), 2 at the laparotomic approach (19) (35), 8 at the laparoscopic approach (22) (36) ϯϮϳ
(37) (38) (39) (40) (41) (42) and 4 at the robotic approach (23) (24) (43) (44). There were 5 ϯϮϴ
retrospective studies  (19) (34) (36) (39) (41), 7 prospective studies (22) (23) (24) (30) (35) ϯϮϵ
(38) (44), 2 randomised studies (37) (40) and 2 retrospective surveys using a prospective ϯϯϬ
database (42) (43). The age criterion varied among the studies: it was 63, 65, 70, 75 or 80 ϯϯϭ
years. There were also differences from a methodological viewpoint: some of the studies ϯϯϮ
compared two surgical approaches in the management of endometrial cancer in elderly ϯϯϯ
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women, while the others compared a single approach in elderly women versus younger ϯϯϰ
women. The studies are summarised in Table 1. ϯϯϱ
ϯϯϲ
Perioperative data ϯϯϳ
ϯϯϴ
 The first results collected concern perioperative data. The Susini study comparing the ϯϯϵ
vaginal approach to laparotomy in patients aged over 70 years found a shorter operative time ϯϰϬ
in the vaginal group (p=0.01) (34). In their study comparing laparotomy in patients aged over ϯϰϭ
and under 70 years, Vaknin et al. did not find a difference in operative time between the age ϯϰϮ
groups (35); neither did Lachance et al. in their study (19). Among the studies comparing ϯϰϯ
laparoscopy and laparotomy in elderly women, only the study by Scribner et al., with a cut-ϯϰϰ
off age of 65 years, found a shorter operative time in the laparotomy group (p=0.0001) (36). ϯϰϱ
The study by Bogani et al. did not find significant difference in operative time between the ϯϰϲ
laparoscopic group and the laparotomic group (42). Studies comparing laparoscopy in elderly ϯϰϳ
women with laparoscopy in younger women did not find  significant difference in operative ϯϰϴ
time between the two groups (22, 39, 41). The study comparing laparotomy with robotic ϯϰϵ
surgery found a shorter operative time in the laparotomy group (p=0.009) (44). Vaknin et al., ϯϱϬ
looking at management of endometrial cancer by robotic surgery, found a similar operative ϯϱϭ
time in patients aged over and under 70 years (253 min vs 243 min) (24); similar results were ϯϱϮ
found by Lowe et al., who looked at the robotic approach in patients aged over and under 80 ϯϱϯ
years (192 min vs 167 min) (43) and by Zeng et al. in patients aged <70 years, 70–80 years ϯϱϰ
and >80 years (23). Hence operative time for mini-invasive surgery is not longer in elderly ϯϱϱ
women with endometrial cancer than in younger women. Only Scribner et al. found a longer ϯϱϲ
operative time for laparoscopy compared with laparotomy (36) and Lavoué et al. for robotic ϯϱϳ
surgery compared with laparotomy (44). This result is not against use of laparoscopy in this ϯϱϴ
indication because the procedure is the same duration regardless of age and the study is quite ϯϱϵ
old (2001). However, it does provide a reminder of the learning curve required by surgeons in ϯϲϬ
order to perform this procedure by laparoscopy in a safe and sufficiently short manner (45)͘ϯϲϭ
With regard to blood loss and transfusion rate, the study by Susini et al. found significantly ϯϲϮ
less blood loss in the vaginal approach group than in the laparotomy group (p=0.01), but no ϯϲϯ
significant difference between these two groups in terms of transfusion rate (34). Conversely, ϯϲϰ
Scribner et al. found a higher transfusion rate in the laparoscopy group (p<0.0001) but no ϯϲϱ
significant difference in blood loss between the laparoscopy group and the laparotomy group ϯϲϲ
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(36). The Lachance study comparing laparotomy in different age groups did not find a ϯϲϳ
significant difference in blood loss (19); similarly the Vaknin study did not find a difference ϯϲϴ
in terms of transfusion (35) in women aged over or under 70 years who underwent a ϯϲϵ
laparotomy. The Bogani et al. study comparing laparoscopy with laparotomy in women aged ϯϳϬ
over 75 years found significantly less blood loss in the laparoscopy group (p=0.005) but no ϯϳϭ
difference between the 2 groups in terms of transfusions (42). However Ghezzi et al. report a ϯϳϮ
lower rate of transfusions in the laparoscopy group (p<0.05) (38). Studies comparing ϯϳϯ
laparoscopy in elderly women with laparoscopy in younger women did not find any ϯϳϰ
significant differences between these two groups, in terms of either blood loss or transfusion ϯϳϱ
rate (22, 39, 41). Robotic surgery was associated with less blood loss when compared to ϯϳϲ
laparotomy (p=0.0001) (44), and there was no significant difference in blood loss between ϯϳϳ
older and younger women (23) (24) (43). Hence, blood loss is equivalent in elderly women ϯϳϴ
and younger women for a given surgical approach, and is higher for laparotomy compared ϯϳϵ
with laparoscopy and robotic surgery (42) (44). ϯϴϬ
Studies comparing outcomes of laparoscopic and robotic modalities in elderly women versus ϯϴϭ
younger women found a similar rate of conversion to laparotomy in both groups (22, 23, 39, ϯϴϮ
40, 41, 43). Only one study, the randomised Gynecologic Oncology Group (GOG) ϯϴϯ
LAP2 Trial, found a higher rate of conversion for more advanced age (OR = 1.27; 95% CI: ϯϴϰ
1.14 to 1.42 per additional decade) (37). According to the literature, laparoscopic or robotic ϯϴϱ
surgery in elderly patients is not associated with a higher rate of conversion to laparotomy. ϯϴϲ
The comparative perioperative data are summarised in Table 2. ϯϴϳ
ϯϴϴ
Complications  ϯϴϵ
ϯϵϬ
Other observations concern perioperative and postoperative complications. In this ϯϵϭ
regard, Susini et al. did not find a significant difference in the number of severe complications ϯϵϮ
that occurred in patients aged over 70 years who underwent a surgery by the vaginal route or ϯϵϯ
who by laparotomy (19). None of the studies comparing laparoscopy with laparotomy in ϯϵϰ
elderly women found a statistically significant difference in perioperative complications (36, ϯϵϱ
38, 40, 42). However, two studies have shown that there are significantly fewer postoperative ϯϵϲ
complications in the laparoscopy group than in the laparotomy group (15/33, p=0.002 (36) ϯϵϳ
and 5/24, p=0.05 (42) respectively). The other studies did not find a significant difference ϯϵϴ
between the laparoscopy group and the laparotomy group in terms of perioperative ϯϵϵ
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complications (0% versus 5% (38) and 5.3% versus 4.3% (40)) or postoperative ϰϬϬ
complications (6.3% versus 9.5% (38) and 23.7% versus 17.4% (40)).  ϰϬϭ
Studies looking at outcomes in elderly versus younger women following laparoscopy did not ϰϬϮ
find any significant differences between the two groups in terms of overall complications ϰϬϯ
(6.4% versus 2.7%) (39), perioperative complications (4.2% versus 1.7%) or postoperative ϰϬϰ
complications (25% versus 23.3%) (22). Similar findings were reported in a study comparing ϰϬϱ
laparotomy outcomes in women aged over versus under 70 years in terms of overall ϰϬϲ
complications (41.7% vs 41.9%) (35), and in a study comparing outcomes following robotic ϰϬϳ
surgery (24). However, De Marzi et al., looking at laparotomy, found a higher rate of ϰϬϴ
perioperative complications in women aged over 75 years (23% vs 9%, p=0.032) (30). ϰϬϵ
Interestingly, this significant difference vanishes if a cut-off age of 80 years is used (30). The ϰϭϬ
study by Lowe et al. looking at robotic surgery in patients aged over versus under 80 years ϰϭϭ
did not find more perioperative complications in the older women but it did find more ϰϭϮ
postoperative complications in the older group (33% vs 13%; p=0.022) (43). Similar findings ϰϭϯ
were reported in another study on robotic surgery that divided patients into 3 age groups: the ϰϭϰ
rate of perioperative complications was similar in the 3 groups (0.5% vs 0% vs 3%), while ϰϭϱ
there was a higher rate of grade III or IV (Clavien Dindo classification (46)) postoperative ϰϭϲ
complications in patients aged over 80 years compared to those aged below 80 years (10% vs ϰϭϳ
1% vs 0%; p=0.0035) (23). Lavoué et al., comparing the robotic approach with laparotomy, ϰϭϴ
found significantly more Clavien Dindo grade I/II postoperative complications in the ϰϭϵ
laparotomy group (17% vs 60%; p<0.0001) but no difference was found with regard to grade ϰϮϬ
III/IV complications (44). The comparative data concerning perioperative and postoperative ϰϮϭ
complications are summarised in Table 3. ϰϮϮ
For a given surgical approach, elderly patients do not have more perioperative complications ϰϮϯ
than younger patients. However, surgical management of endometrial cancers in this age ϰϮϰ
group by laparotomy is associated with more morbidity than vaginal, laparoscopic or robot-ϰϮϱ
assisted modalities in terms of operative time, blood loss and perioperative complications. ϰϮϲ
  ϰϮϳ
ϰϮϴ
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Length of hospital stay  ϰϮϵ
ϰϯϬ
Susini et al. found that the hospital stay was shorter in women operated on vaginally ϰϯϭ
approach (6 days (d) vs 10 d; p=0.05 (34)). Studies comparing laparoscopy with laparotomy ϰϯϮ
showed that the hospital stay was significantly shorter for patients who underwent ϰϯϯ
laparoscopy (3 d versus 5.6 d; p<0.0001 (36); 2 d versus 6 d; p<0.05 (42); 2.5 d versus 7 d; ϰϯϰ
p<0.05 (38)). The randomised GOG LAP2 trial (37) found that the proportion of patients ϰϯϱ
requiring more than 2 days of hospitalisation after surgery was significantly lower in the ϰϯϲ
laparoscopy group than in the laparotomy group (52% versus 94%; p<0.0001). In the two ϰϯϳ
studies comparing laparotomy in elderly women of different ages, one of them did not find a ϰϯϴ
significant difference in length of hospital stay in women between older vs younger than 70 ϰϯϵ
years (35), while De Marzi et al. found a longer stay in women aged over 80 years (9.3 d vs ϰϰϬ
7.7 d; p=0.036 (30)). Studies comparing laparoscopy with the robotic approach in elderly ϰϰϭ
women of different ages did not find a significant difference between the 2 or 3 age groups in ϰϰϮ
terms of length of hospital stay (22, 23, 24, 39, 40, 43). In a comparison of robotic surgery ϰϰϯ
with laparotomy, length of hospital stay was longer in women aged over 70 years who ϰϰϰ
underwent a laparotomy (3.1 d vs 8 d; p<0.0001 (43)). ϰϰϱ
The use of mini-invasive surgery (laparoscopy and robotic) to manage endometrial cancers in ϰϰϲ
elderly women is associated with a shorter hospital stay than laparotomy or the vaginal route; ϰϰϳ
furthermore, the elderly women undergoing mini-invasive surgery are not hospitalized longer ϰϰϴ
than younger women (Table 4). ϰϰϵ
ϰϱϬ
Treatment of endometrial cancers is primarily surgical. Historically, surgery was ϰϱϭ
performed by laparotomy, but in the last decade several studies have demonstrated the ϰϱϮ
feasibility and advantages of laparoscopy and robotic surgery in the management of ϰϱϯ
endometrial cancer in all patients (47) (48) and consequently have driven change in surgical ϰϱϰ
practice in favour of laparoscopy and robotic surgery, the optimal surgical modalities with the ϰϱϱ
lowest morbidity in this indication. Nevertheless, when it comes to surgical management of ϰϱϲ
“elderly” patients with endometrial cancer, today’s medico-surgical teams have still not ϰϱϳ
converted to the mini-invasive approach. Yet the present literature review shows that, in spite ϰϱϴ
of the higher burden of comorbidities, elderly patients can also benefit from mini-invasive ϰϱϵ
surgery to manage their endometrial cancer, in terms of blood loss, perioperative ϰϲϬ
complications and length of hospital stay. ϰϲϭ
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Surgical staging ϰϲϮ
ϰϲϯ
Surgical management of endometrial cancers notably includes pelvic and/or lumbo-ϰϲϰ
aortic nodal staging. Among the previously cited studies, only the studies by Vaknin et al.ϰϲϱ
comparing laparotomy or robotic surgery in patients older vs younger than 70 years found that ϰϲϲ
significantly more lymph nodes were removed in patients below 70 years (4 vs 10.4; p<0.001 ϰϲϳ
(35) and 10 vs 13; p=0.00613 (24)). Studies comparing the number of lymph nodes removed ϰϲϴ
by laparoscopy or laparotomy in elderly women with endometrial cancer aged over vs under ϰϲϵ
65 years (36) or 75 years (42), or by robotic surgery compared to laparotomy (44) or those ϰϳϬ
comparing the number of lymph nodes removed by laparoscopy in women aged over vs ϰϳϭ
below 65 years (22, 39) or 70 years (41), similarly by laparotomy (19) or by robotic surgery ϰϳϮ
(23, 43) did not find a significant difference in terms of the number of lymph nodes removed ϰϳϯ
as function of patient age (Table 5). According to these studies, mini-invasive surgery appears ϰϳϰ
to be a completely satisfactory technique for performing lymph node staging in endometrial ϰϳϱ
cancers in elderly women. ϰϳϲ
From an oncology viewpoint, it can be seen that there is no significant difference in ϰϳϳ
the number of lymph nodes removed as a function of age for a given surgical approach, ϰϳϴ
except in the two studies by Vaknin et al. This could be explained by the fact that the ϰϳϵ
surgeons in these two studies perform less-complete lymphadenectomies when patients are ϰϴϬ
older, even though their disease is more aggressive. This gives rise to an important question ϰϴϭ
not answered by the present literature review: independently of the lymph node number, do ϰϴϮ
surgeons perform lymphadenectomy in elderly patients when this is recommended? It is ϰϴϯ
known that in general oncological surgery, elderly patients are often undertreated (49) so it is ϰϴϰ
pertinent to ask whether this is the case for endometrial cancer. Today, lymphadenectomy in ϰϴϱ
the management of endometrial cancers is recommended or not as function of FIGO stage and ϰϴϲ
tumour histology. Lymphadenectomy extends operative time, itself a morbidity factor in ϰϴϳ
women aged over 80 years, given that a 30-minute increase leads to a 17% increase in the ϰϴϴ
complication rate (50) in this age group. Furthermore, it is associated with perioperative ϰϴϵ
(vascular and neural) and postoperative (lymphoedema and neurological) risks. However, in ϰϵϬ
view of the higher severity of endometrial cancer in elderly patients, it would be legitimate to ϰϵϭ
perform lymphadenectomies more often. Further studies are required in order to determine ϰϵϮ
whether nodal staging is performed or not in this age group and, if it is performed, to ϰϵϯ
determine the associated morbidity, given that this information is not found in the literature. ϰϵϰ
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CONCLUSION ϰϵϱ
 The incidence of endometrial cancer is increasing in line with the aging of the female ϰϵϲ
population. In elderly women, this cancer is more aggressive yet often undertreated. This ϰϵϳ
aggressiveness calls for optimal surgical management by the mini-invasive approach ϰϵϴ
(including a lymphadenectomy when recommended) subject to oncogeriatric evaluation of ϰϵϵ
frailty. Although frailty is better than age at predicting surgical morbidity, it is currently ϱϬϬ
poorly defined — there is therefore a need to develop a short, quick score for predicting ϱϬϭ
surgical morbidity.  ϱϬϮ
  ϱϬϯ
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ϴ͘ ŽŵŵŽŶƉĞƌŝŽƉĞƌĂƚŝǀĞŽŵƉůŝĐĂƚŝŽŶƐŝŶKůĚĞƌWĂƚŝĞŶƚƐ΀/ŶƚĞƌŶĞƚ΁͘΀ĐŝƚĠϮϴŵĂƌƐϱϯϬ
ϮϬϭϰ΁͘ŝƐƉŽŶŝďůĞƐƵƌ͗ϱϯϭ
ŚƚƚƉ͗ͬͬǁǁǁ͘ƐƉƌŝŶŐĞƌ͘ĐŽŵͬĐĚĂͬĐŽŶƚĞŶƚͬĚŽĐƵŵĞŶƚͬĐĚĂͺĚŽǁŶůŽĂĚĚŽĐƵŵĞŶƚͬϵϳϴϭϰϰϭϵϲϵϵϴϱϯϮ
ϵͲĐϮϵ͘ƉĚĨ͍^'t/сϬͲϬͲϰϱͲϭϭϱϮϵϯϵͲƉϭϳϰϭϮϴϭϴϬϱϯϯ
ϵ͘ dĞƌƌĞƚ͕ƌŽǌ:ͲW͘΀ĞĨŝŶŝƚŝŽŶĂŶĚŽƵƚůŝŶĞŽŶŐĞƌŝĂƚƌŝĐŽŶĐŽůŽŐǇ΁͘WƌŽŐŶhƌŽů:ƐƐŽĐϱϯϰ
&ƌhƌŽů^ŽĐŝĠƚĠ&ƌhƌŽů͘ŶŽǀϮϬϬϵ͖ϭϵ^ƵƉƉůϯ͗^ϳϱ̻ϵ͘ϱϯϱ
ϭϬ͘ ,ĂŵĂŬĞƌD͕sŽƐ'͕^ŵŽƌĞŶďƵƌŐ,͕ĚĞZŽŽŝũ^͕ǀĂŶDƵŶƐƚĞƌ͘dŚĞǀĂůƵĞŽĨϱϯϲ
ŐĞƌŝĂƚƌŝĐĂƐƐĞƐƐŵĞŶƚƐŝŶƉƌĞĚŝĐƚŝŶŐƚƌĞĂƚŵĞŶƚƚŽůĞƌĂŶĐĞĂŶĚĂůůͲĐĂƵƐĞŵŽƌƚĂůŝƚǇŝŶŽůĚĞƌϱϯϳ
ƉĂƚŝĞŶƚƐǁŝƚŚĐĂŶĐĞƌ͘dŚĞŽŶĐŽůŽŐŝƐƚ͘ϮϬϭϮ͖ϭϳ;ϭϭͿ͗ϭϰϯϵ̻ϰϵ͘ϱϯϴ
ϭϭ͘ ^ŽƵďĞǇƌĂŶW͕ĞůůĞƌĂ͕'ŽǇĂƌĚ:͕,Ğŝƚǌ͕ƵƌĠ,͕ZŽƵƐƐĞůŽƚ,͕ĞƚĂů͘^ĐƌĞĞŶŝŶŐĨŽƌϱϯϵ
sƵůŶĞƌĂďŝůŝƚǇŝŶKůĚĞƌĂŶĐĞƌWĂƚŝĞŶƚƐ͗dŚĞKEK'WƌŽƐƉĞĐƚŝǀĞDƵůƚŝĐĞŶƚĞƌŽŚŽƌƚϱϰϬ
^ƚƵĚǇ͘WůŽ^KŶĞ͘ϮϬϭϰ͖ϵ;ϭϮͿ͗ĞϭϭϱϬϲϬ͘ϱϰϭ
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ϭϮ͘ DŝƚŬĂD͘dŽŽĨĞǁŽůĚĞƌƉĂƚŝĞŶƚƐŝŶĐĂŶĐĞƌƚƌŝĂůƐ͗ĞǆƉĞƌƚƐƐĂǇĚŝƐƉĂƌŝƚǇĂĨĨĞĐƚƐƌĞƐĞĂƌĐŚϱϰϮ
ƌĞƐƵůƚƐĂŶĚĐĂƌĞ͘:D͘ϮũƵŝůůϮϬϬϯ͖ϮϵϬ;ϭͿ͗Ϯϳ̻ϴ͘ϱϰϯ
ϭϯ͘ >ĞǁŝƐ:,͕<ŝůŐŽƌĞD>͕'ŽůĚŵĂŶW͕dƌŝŵďůĞ>͕<ĂƉůĂŶZ͕DŽŶƚĞůůŽD:͕ĞƚĂů͘ϱϰϰ
WĂƌƚŝĐŝƉĂƚŝŽŶŽĨƉĂƚŝĞŶƚƐϲϱǇĞĂƌƐŽĨĂŐĞŽƌŽůĚĞƌŝŶĐĂŶĐĞƌĐůŝŶŝĐĂůƚƌŝĂůƐ͘:ůŝŶKŶĐŽůKĨĨ:ŵϱϰϱ
^ŽĐůŝŶKŶĐŽů͘ϭĂǀƌϮϬϬϯ͖Ϯϭ;ϳͿ͗ϭϯϴϯ̻ϵ͘ϱϰϲ
ϭϰ͘ ƵĚŝƐŝŽZ͕WŽƉĞ͕ZĂŵĞƐŚ,^:͕'ĞŶŶĂƌŝZ͕ǀĂŶ>ĞĞƵǁĞŶ>͕tĞƐƚ͕ĞƚĂů͘ǁŝƚŚWϱϰϳ
ƉĂƌƚŝĐŝƉĂŶƚƐ͘^ŚĂůůǁĞŽƉĞƌĂƚĞ͍WƌĞŽƉĞƌĂƚŝǀĞĂƐƐĞƐƐŵĞŶƚŝŶĞůĚĞƌůǇĐĂŶĐĞƌƉĂƚŝĞŶƚƐ;WͿϱϰϴ
ĐĂŶŚĞůƉ͘^/K'ƐƵƌŐŝĐĂůƚĂƐŬĨŽƌĐĞƉƌŽƐƉĞĐƚŝǀĞƐƚƵĚǇ͘ƌŝƚZĞǀKŶĐŽů,ĞŵĂƚŽů͘ĨĠǀƌϱϰϵ
ϮϬϬϴ͖ϲϱ;ϮͿ͗ϭϱϲ̻ϲϯ͘ϱϱϬ
ϭϱ͘ 'ŝĂŶŶŝĐĞZ͕&Žƚŝ͕WŽĞƌŝŽ͕DĂƌĂŶĂ͕DĂŶĐƵƐŽ^͕^ĐĂŵďŝĂ'͘WĞƌŝŽƉĞƌĂƚŝǀĞϱϱϭ
ŵŽƌďŝĚŝƚǇĂŶĚŵŽƌƚĂůŝƚǇŝŶĞůĚĞƌůǇŐǇŶĞĐŽůŽŐŝĐĂůŽŶĐŽůŽŐŝĐĂůƉĂƚŝĞŶƚƐ;хͬсϳϬzĞĂƌƐͿďǇƚŚĞϱϱϮ
ŵĞƌŝĐĂŶ^ŽĐŝĞƚǇŽĨŶĞƐƚŚĞƐŝŽůŽŐŝƐƚƐƉŚǇƐŝĐĂůƐƚĂƚƵƐĐůĂƐƐĞƐ͘ŶŶ^ƵƌŐKŶĐŽů͘ĨĠǀƌϱϱϯ
ϮϬϬϰ͖ϭϭ;ϮͿ͗Ϯϭϵ̻Ϯϱ͘ϱϱϰ
ϭϲ͘ ZĞǀĞŶŝŐ>D͕ĂŶƚĞƌ:͕dĂǇůŽƌD͕dĂŝ͕^ǁĞĞŶĞǇ:&͕^ĂƌŵŝĞŶƚŽ:D͕ĞƚĂů͘dŽŽĨƌĂŝůϱϱϱ
ĨŽƌƐƵƌŐĞƌǇ͍/ŶŝƚŝĂůƌĞƐƵůƚƐŽĨĂůĂƌŐĞŵƵůƚŝĚŝƐĐŝƉůŝŶĂƌǇƉƌŽƐƉĞĐƚŝǀĞƐƚƵĚǇĞǆĂŵŝŶŝŶŐϱϱϲ
ƉƌĞŽƉĞƌĂƚŝǀĞǀĂƌŝĂďůĞƐƉƌĞĚŝĐƚŝǀĞŽĨƉŽŽƌƐƵƌŐŝĐĂůŽƵƚĐŽŵĞƐ͘:ŵŽůů^ƵƌŐ͘ŽĐƚϱϱϳ
ϮϬϭϯ͖Ϯϭϳ;ϰͿ͗ϲϲϱ̻ϳϬ͘Ğϭ͘ϱϱϴ
ϭϳ͘ ^ŝĞŐĞůZ͕EĂŝƐŚĂĚŚĂŵ͕:ĞŵĂů͘ĂŶĐĞƌƐƚĂƚŝƐƚŝĐƐ͕ϮϬϭϯ͘ĂŶĐĞƌ:ůŝŶ͘ũĂŶǀϱϱϵ
ϮϬϭϯ͖ϲϯ;ϭͿ͗ϭϭ̻ϯϬ͘ϱϲϬ
ϭϴ͘ WĂƌŬ:z͕EĂŵ:Ͳ,͕<ŝŵzͲd͕<ŝŵzͲD͕<ŝŵ:Ͳ,͕<ŝŵͲz͕ĞƚĂů͘WŽŽƌƉƌŽŐŶŽƐŝƐŽĨƵƚĞƌŝŶĞϱϲϭ
ƐĞƌŽƵƐĐĂƌĐŝŶŽŵĂĐŽŵƉĂƌĞĚǁŝƚŚŐƌĂĚĞϯĞŶĚŽŵĞƚƌŝŽŝĚĐĂƌĐŝŶŽŵĂŝŶĞĂƌůǇƐƚĂŐĞƉĂƚŝĞŶƚƐ͘ϱϲϮ
sŝƌĐŚŽǁƐƌĐŚ/Ŷƚ:WĂƚŚŽů͘ŵĂƌƐϮϬϭϯ͖ϰϲϮ;ϯͿ͗Ϯϴϵ̻ϵϲ͘ϱϲϯ
ϭϵ͘ >ĂĐŚĂŶĐĞ:͕ǀĞƌĞƚƚE͕'ƌĞĞƌ͕DĂŶĚĞů>͕^ǁŝƐŚĞƌ͕dĂŵŝŵŝ,͕ĞƚĂů͘dŚĞĞĨĨĞĐƚŽĨϱϲϰ
ĂŐĞŽŶĐůŝŶŝĐĂůͬƉĂƚŚŽůŽŐŝĐĨĞĂƚƵƌĞƐ͕ƐƵƌŐŝĐĂůŵŽƌďŝĚŝƚǇ͕ĂŶĚŽƵƚĐŽŵĞŝŶƉĂƚŝĞŶƚƐǁŝƚŚϱϲϱ
ĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ͘'ǇŶĞĐŽůKŶĐŽů͘ũƵŝŶϮϬϬϲ͖ϭϬϭ;ϯͿ͗ϰϳϬ̻ϱ͘ϱϲϲ
ϮϬ͘ 'ŽŶǌĂůĞǌͲZŽĚŝůůĂ/͕ŽŝǆD͕sĞƌŶĂs͕DƵŹŽǌ͕ƐƚĠǀĞǌ:͕:ƵďĞƚĞz͕ĞƚĂů͘WĂƚŝĞŶƚĂŐĞϱϲϳ
ĂŶĚďŝŽůŽŐŝĐĂůĂŐŐƌĞƐƐŝǀĞŶĞƐƐŽĨĞŶĚŽŵĞƚƌŝĂůĐĂƌĐŝŶŽŵĂ͘ŶƚŝĐĂŶĐĞƌZĞƐ͘ŵĂŝϱϲϴ
ϮϬϭϮ͖ϯϮ;ϱͿ͗ϭϴϭϳ̻ϮϬ͘ϱϲϵ
Ϯϭ͘ :ŽůůǇ^͕sĂƌŐĂƐ͕<ƵŵĂƌd͕tĞŝŶĞƌ^͕ƌĂďďŝŶƐ^͕ŚĞŶWz͕ĞƚĂů͘dŚĞŝŵƉĂĐƚŽĨĂŐĞϱϳϬ
ŽŶůŽŶŐͲƚĞƌŵŽƵƚĐŽŵĞŝŶƉĂƚŝĞŶƚƐǁŝƚŚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌƚƌĞĂƚĞĚǁŝƚŚƉŽƐƚŽƉĞƌĂƚŝǀĞϱϳϭ
ƌĂĚŝĂƚŝŽŶ͘'ǇŶĞĐŽůKŶĐŽů͘ŽĐƚϮϬϬϲ͖ϭϬϯ;ϭͿ͗ϴϳ̻ϵϯ͘ϱϳϮ
ϮϮ͘ ^ŝĞƐƚŽ'͕hĐĐĞůůĂ^͕'ŚĞǌǌŝ&͕ƌŽŵŝ͕ĞĨŝƌŽ&͕^ĞƌĂƚŝD͕ĞƚĂů͘^ƵƌŐŝĐĂůĂŶĚƐƵƌǀŝǀĂůϱϳϯ
ŽƵƚĐŽŵĞƐŝŶŽůĚĞƌǁŽŵĞŶǁŝƚŚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌƚƌĞĂƚĞĚďǇůĂƉĂƌŽƐĐŽƉǇ͘DĞŶŽƉĂƵƐĞEzϱϳϰ
E͘ũƵŝŶϮϬϭϬ͖ϭϳ;ϯͿ͗ϱϯϵ̻ϰϰ͘ϱϳϱ
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Ϯϯ͘ ĞŶŐy͕>ĂǀŽƵĞs͕>ĂƵ^͕WƌĞƐƐ:͕ďŝƚďŽů:͕'ŽƚůŝĞďZ͕ĞƚĂů͘KƵƚĐŽŵĞŽĨZŽďŽƚŝĐϱϳϲ
^ƵƌŐĞƌǇĨŽƌŶĚŽŵĞƚƌŝĂůĂŶĐĞƌĂƐĂ&ƵŶĐƚŝŽŶŽĨWĂƚŝĞŶƚŐĞ͘/Ŷƚ:'ǇŶĞĐŽůĂŶĐĞƌKĨĨ:/Ŷƚϱϳϳ
'ǇŶĞĐŽůĂŶĐĞƌ^ŽĐ͘ϮϲĨĠǀƌϮϬϭϱ͖ϱϳϴ
Ϯϰ͘ sĂŬŶŝŶ͕WĞƌƌŝd͕>ĂƵ^͕ĞůĂŶĚ͕ƌƵŵŵŽŶĚE͕ZŽƐďĞƌŐĞƌ͕ĞƚĂů͘KƵƚĐŽŵĞĂŶĚϱϳϵ
ƋƵĂůŝƚǇŽĨůŝĨĞŝŶĂƉƌŽƐƉĞĐƚŝǀĞĐŽŚŽƌƚŽĨƚŚĞĨŝƌƐƚϭϬϬƌŽďŽƚŝĐƐƵƌŐĞƌŝĞƐĨŽƌĞŶĚŽŵĞƚƌŝĂůϱϴϬ
ĐĂŶĐĞƌ͕ǁŝƚŚĨŽĐƵƐŽŶĞůĚĞƌůǇƉĂƚŝĞŶƚƐ͘/Ŷƚ:'ǇŶĞĐŽůĂŶĐĞƌKĨĨ:/Ŷƚ'ǇŶĞĐŽůĂŶĐĞƌ^ŽĐ͘ŶŽǀϱϴϭ
ϮϬϭϬ͖ϮϬ;ϴͿ͗ϭϯϲϳ̻ϳϯ͘ϱϴϮ
Ϯϱ͘ ƌĞĂƐŵĂŶt͘ZĞǀŝƐĞĚ&/'KƐƚĂŐŝŶŐĨŽƌĐĂƌĐŝŶŽŵĂŽĨƚŚĞĞŶĚŽŵĞƚƌŝƵŵ͘/Ŷƚ:'ǇŶĂĞĐŽůϱϴϯ
KďƐƚĞƚKĨĨKƌŐĂŶ/Ŷƚ&ĞĚ'ǇŶĂĞĐŽůKďƐƚĞƚ͘ŵĂŝϮϬϬϵ͖ϭϬϱ;ϮͿ͗ϭϬϵ͘ϱϴϰ
Ϯϲ͘ >ĞĚŝĂŐŶŽƐƚŝĐ΀/ŶƚĞƌŶĞƚ΁͘&ŽŶĚĂƚŝŽŶZƉŽƵƌůĂƌĞĐŚĞƌĐŚĞƐƵƌůĞĐĂŶĐĞƌ͘΀ĐŝƚĠϭϰĨĠǀƌϱϴϱ
ϮϬϭϱ΁͘ŝƐƉŽŶŝďůĞƐƵƌ͗ŚƚƚƉ͗ͬͬǁǁǁ͘ĨŽŶĚĂƚŝŽŶͲĂƌĐ͘ŽƌŐͬ>ĞͲĐĂŶĐĞƌͲĐŚĞǌͲůĂͲƉĞƌƐŽŶŶĞͲϱϴϲ
ĂŐĞĞͬŽŶĐŽŐĞƌŝĂƚƌŝĞͲůĞͲĚŝĂŐŶŽƐƚŝĐ͘Śƚŵůϱϴϳ
Ϯϳ͘ >Ăǆ^&͘΀ƵĂůŝƐƚŝĐŵŽĚĞůŽĨŵŽůĞĐƵůĂƌƉĂƚŚŽŐĞŶĞƐŝƐŝŶĞŶĚŽŵĞƚƌŝĂůĐĂƌĐŝŶŽŵĂ΁͘ϱϴϴ
ĞŶƚƌĂůďůĂƚƚ&ƺƌ'ǇŶćŬŽů͘ũĂŶǀϮϬϬϮ͖ϭϮϰ;ϭͿ͗ϭϬ̻ϲ͘ϱϴϵ
Ϯϴ͘ &ůĞŵŝŶŐE͕>ĞŶƚǌ^͕ĂƐƐ/͕>ŝ:͕<ĂƌůĂŶz͕tĂůƐŚ^͘/ƐŽůĚĞƌĂŐĞĂƉŽŽƌƉƌŽŐŶŽƐƚŝĐϱϵϬ
ĨĂĐƚŽƌŝŶƐƚĂŐĞ/ĂŶĚ//ĞŶĚŽŵĞƚƌŝŽŝĚĞŶĚŽŵĞƚƌŝĂůĂĚĞŶŽĐĂƌĐŝŶŽŵĂ͍'ǇŶĞĐŽůKŶĐŽů͘ĨĠǀƌϱϵϭ
ϮϬϭϭ͖ϭϮϬ;ϮͿ͗ϭϴϵ̻ϵϮ͘ϱϵϮ
Ϯϵ͘ ůĞŬƚŝĂƌ<D͕sĞŶŬĂƚƌĂŵĂŶ͕ďƵͲZƵƐƚƵŵE͕ĂƌĂŬĂƚZZ͘/ƐĞŶĚŽŵĞƚƌŝĂůĐĂƌĐŝŶŽŵĂϱϵϯ
ŝŶƚƌŝŶƐŝĐĂůůǇŵŽƌĞĂŐŐƌĞƐƐŝǀĞŝŶĞůĚĞƌůǇƉĂƚŝĞŶƚƐ͍ĂŶĐĞƌ͘ϭĚĠĐϮϬϬϯ͖ϵϴ;ϭϭͿ͗Ϯϯϲϴ̻ϳϳ͘ϱϵϰ
ϯϬ͘ ĞDĂƌǌŝW͕KƚƚŽůŝŶĂ:͕DĂŶŐŝůŝ'͕ZĂďĂŝŽƚƚŝ͕&ĞƌƌĂƌŝ͕sŝŐĂŶžZ͕ĞƚĂů͘^ƵƌŐŝĐĂůϱϵϱ
ƚƌĞĂƚŵĞŶƚŽĨĞůĚĞƌůǇƉĂƚŝĞŶƚƐǁŝƚŚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ;шϲϱǇĞĂƌƐͿ͘:'ĞƌŝĂƚƌKŶĐŽů͘ŽĐƚϱϵϲ
ϮϬϭϯ͖ϰ;ϰͿ͗ϯϲϴ̻ϳϯ͘ϱϵϳ
ϯϭ͘ KƵůĚĂŵĞƌ>͕ƵƋƵĞƐŶĞD͕ƌďŝŽŶ&͕ĂƌŝůůŽƚ/͕DĂƌƌĞƚ,͕ŽĚǇ'͘/ŵƉĂĐƚĚĞůĂƉƌŝƐĞĞŶϱϵϴ
ĐŚĂƌŐĞƚŚĠƌĂƉĞƵƚŝƋƵĞƐƵƌůĂƐƵƌǀŝĞĐŚĞǌůĞƐĨĞŵŵĞƐƚƌğƐąŐĠĞƐĂǀĞĐĐĂŶĐĞƌĚĞů͛ĞŶĚŽŵğƚƌĞ͘ϱϵϵ
'ǇŶĠĐŽůŽŐŝĞKďƐƚĠƚƌŝƋƵĞ&Ğƌƚŝů͘ĚĠĐϮϬϭϮ͖ϰϬ;ϭϮͿ͗ϳϱϵ̻ϲϰ͘ϲϬϬ
ϯϮ͘ ŚŵĞĚ͕ĂŵďĂ'͕Ğ'ĞĞƐƚ<͕>ǇŶĐŚ&͘dŚĞŝŵƉĂĐƚŽĨƐƵƌŐĞƌǇŽŶƐƵƌǀŝǀĂůŽĨĞůĚĞƌůǇϲϬϭ
ǁŽŵĞŶǁŝƚŚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌŝŶƚŚĞ^ZƉƌŽŐƌĂŵĨƌŽŵϭϵϵϮʹϮϬϬϮ͘'ǇŶĞĐŽůKŶĐŽů͘ϭŽĐƚϲϬϮ
ϮϬϬϴ͖ϭϭϭ;ϭͿ͗ϯϱ̻ϰϬ͘ϲϬϯ
ϯϯ͘ EŽƌĚŝŶ:͕ŚŝŶŶ:͕DŽůŽŶĞǇ/͕EĂŝŬZ͕ĚĞĂƌƌŽƐ>ŽƉĞƐ͕DŽŶĂŐŚĂŶ:D͘ŽĞůĚĞƌůǇϲϬϰ
ĐĂŶĐĞƌƉĂƚŝĞŶƚƐĐĂƌĞĂďŽƵƚĐƵƌĞ͍ƚƚŝƚƵĚĞƐƚŽƌĂĚŝĐĂůŐǇŶĞĐŽůŽŐŝĐŽŶĐŽůŽŐǇƐƵƌŐĞƌǇŝŶƚŚĞϲϬϱ
ĞůĚĞƌůǇ͘'ǇŶĞĐŽůKŶĐŽů͘ũƵŝŶϮϬϬϭ͖ϴϭ;ϯͿ͗ϰϰϳ̻ϱϱ͘ϲϬϲ
ϯϰ͘ ^ƵƐŝŶŝd͕DĂƐƐŝ'͕ŵƵŶŶŝ'͕ĂƌƌŝĞƌŽ͕DĂƌĐŚŝŽŶŶŝD͕dĂĚĚĞŝ'͕ĞƚĂů͘sĂŐŝŶĂůϲϬϳ
ŚǇƐƚĞƌĞĐƚŽŵǇĂŶĚĂďĚŽŵŝŶĂůŚǇƐƚĞƌĞĐƚŽŵǇĨŽƌƚƌĞĂƚŵĞŶƚŽĨĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌŝŶƚŚĞϲϬϴ
ĞůĚĞƌůǇ͘'ǇŶĞĐŽůKŶĐŽů͘ĨĠǀƌϮϬϬϱ͖ϵϲ;ϮͿ͗ϯϲϮ̻ϳ͘ϲϬϵ
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 Ϯϯ
ϯϱ͘ sĂŬŶŝŶ͕ĞŶͲŵŝ/͕^ĐŚŶĞŝĚĞƌ͕WĂŶƐŬǇD͕,ĂůƉĞƌŝŶZ͘ĐŽŵƉĂƌŝƐŽŶŽĨϲϭϬ
ƉĞƌŝŽƉĞƌĂƚŝǀĞŵŽƌďŝĚŝƚǇ͕ƉĞƌŝŽƉĞƌĂƚŝǀĞŵŽƌƚĂůŝƚǇ͕ĂŶĚĚŝƐĞĂƐĞͲƐƉĞĐŝĨŝĐƐƵƌǀŝǀĂůŝŶĞůĚĞƌůǇϲϭϭ
ǁŽŵĞŶ;хŽƌсϳϬǇĞĂƌƐͿǀĞƌƐƵƐǇŽƵŶŐĞƌǁŽŵĞŶ;фϳϬǇĞĂƌƐͿǁŝƚŚĞŶĚŽŵĞƚƌŝŽŝĚĞŶĚŽŵĞƚƌŝĂůϲϭϮ
ĐĂŶĐĞƌ͘/Ŷƚ:'ǇŶĞĐŽůĂŶĐĞƌKĨĨ:/Ŷƚ'ǇŶĞĐŽůĂŶĐĞƌ^ŽĐ͘ũƵŝůůϮϬϬϵ͖ϭϵ;ϱͿ͗ϴϳϵ̻ϴϯ͘ϲϭϯ
ϯϲ͘ ^ĐƌŝďŶĞƌ:ƌ͘Z͕tĂůŬĞƌ:>͕:ŽŚŶƐŽŶ'͕DĐDĞĞŬŝŶ^͕'ŽůĚD͕DĂŶŶĞůZ^͘^ƵƌŐŝĐĂůϲϭϰ
DĂŶĂŐĞŵĞŶƚŽĨĂƌůǇͲ^ƚĂŐĞŶĚŽŵĞƚƌŝĂůĂŶĐĞƌŝŶƚŚĞůĚĞƌůǇ͗/Ɛ>ĂƉĂƌŽƐĐŽƉǇ&ĞĂƐŝďůĞ͍ϲϭϱ
'ǇŶĞĐŽůKŶĐŽů͘ĚĠĐϮϬϬϭ͖ϴϯ;ϯͿ͗ϱϲϯ̻ϴ͘ϲϭϲ
ϯϳ͘ tĂůŬĞƌ:>͕WŝĞĚŵŽŶƚĞDZ͕^ƉŝƌƚŽƐED͕ŝƐĞŶŬŽƉ^D͕^ĐŚůĂĞƌƚŚ:͕DĂŶŶĞůZ^͕ĞƚĂů͘ϲϭϳ
>ĂƉĂƌŽƐĐŽƉǇĐŽŵƉĂƌĞĚǁŝƚŚůĂƉĂƌŽƚŽŵǇĨŽƌĐŽŵƉƌĞŚĞŶƐŝǀĞƐƵƌŐŝĐĂůƐƚĂŐŝŶŐŽĨƵƚĞƌŝŶĞϲϭϴ
ĐĂŶĐĞƌ͗'ǇŶĞĐŽůŽŐŝĐKŶĐŽůŽŐǇ'ƌŽƵƉ^ƚƵĚǇ>WϮ͘:ůŝŶKŶĐŽůKĨĨ:ŵ^ŽĐůŝŶKŶĐŽů͘ϭϬŶŽǀϲϭϵ
ϮϬϬϵ͖Ϯϳ;ϯϮͿ͗ϱϯϯϭ̻ϲ͘ϲϮϬ
ϯϴ͘ 'ŚĞǌǌŝ&͕ƌŽŵŝ͕^ŝĞƐƚŽ'͕^ĞƌĂƚŝD͕ŽŐĂŶŝ'͕^ƚƵƌůĂ͕ĞƚĂů͘hƐĞŽĨůĂƉĂƌŽƐĐŽƉǇŝŶϲϮϭ
ŽůĚĞƌǁŽŵĞŶƵŶĚĞƌŐŽŝŶŐŐǇŶĞĐŽůŽŐŝĐƉƌŽĐĞĚƵƌĞƐ͗ŝƐŝƚƚŝŵĞƚŽŽǀĞƌĐŽŵĞŝŶŝƚŝĂůĐŽŶĐĞƌŶƐ͍ϲϮϮ
DĞŶŽƉĂƵƐĞEzE͘ĨĠǀƌϮϬϭϬ͖ϭϳ;ϭͿ͗ϵϲ̻ϭϬϯ͘ϲϮϯ
ϯϵ͘ &ƌĞǇD<͕/ŚŶŽǁ^͕tŽƌůĞǇD::ƌ͕,ĞǇŵĂŶ<W͕<ĞƐƐůĞƌZ͕^ůŽŵŽǀŝƚǌD͕ĞƚĂů͘ϲϮϰ
DŝŶŝŵĂůůǇŝŶǀĂƐŝǀĞƐƚĂŐŝŶŐŽĨĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌŝƐĨĞĂƐŝďůĞĂŶĚƐĂĨĞŝŶĞůĚĞƌůǇǁŽŵĞŶ͘:ϲϮϱ
DŝŶŝŵ/ŶǀĂƐŝǀĞ'ǇŶĞĐŽů͘ĂǀƌϮϬϭϭ͖ϭϴ;ϮͿ͗ϮϬϬ̻ϰ͘ϲϮϲ
ϰϬ͘ ŝũĞŶD͕ĚĞŽĐŬ',͕sĞƌŵĞƵůĞŶ<D͕ƌƚƐ,:'͕ƚĞƌƌƵŐŐĞ,'͕ǀĂŶĚĞƌ^ŝũĚĞZ͕ĞƚϲϮϳ
Ăů͘>ĂƉĂƌŽƐĐŽƉŝĐŚǇƐƚĞƌĞĐƚŽŵǇŝƐƉƌĞĨĞƌƌĞĚŽǀĞƌůĂƉĂƌŽƚŽŵǇŝŶĞĂƌůǇĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌϲϮϴ
ƉĂƚŝĞŶƚƐ͕ŚŽǁĞǀĞƌŶŽƚĐŽƐƚĞĨĨĞĐƚŝǀĞŝŶƚŚĞǀĞƌǇŽďĞƐĞ͘Ƶƌ:ĂŶĐĞƌKǆĨŶŐůϭϵϵϬ͘ƐĞƉƚϲϮϵ
ϮϬϭϭ͖ϰϳ;ϭϰͿ͗Ϯϭϱϴ̻ϲϱ͘ϲϯϬ
ϰϭ͘ WĞƌƌŽŶĞD͕ŝDĂƌĐŽďĞƌĂƌĚŝŶŽ͕ZŽƐƐŝD͕WŽǌǌĂƚŝ&͕WĞůůĞŐƌŝŶŝ͕WƌŽĐĂĐĐŝŶŝD͕ĞƚĂů͘ϲϯϭ
>ĂƉĂƌŽƐĐŽƉŝĐǀĞƌƐƵƐůĂƉĂƌŽƚŽŵŝĐĂƉƉƌŽĂĐŚƚŽĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ͘Ƶƌ:'ǇŶĂĞĐŽůKŶĐŽů͘ϲϯϮ
ϮϬϭϮ͖ϯϯ;ϰͿ͗ϯϳϲ̻ϴϭ͘ϲϯϯ
ϰϮ͘ ŽŐĂŶŝ'͕ƌŽŵŝ͕hĐĐĞůůĂ^͕^ĞƌĂƚŝD͕ĂƐĂƌŝŶ:͕DĂƌŝĂŶŝ͕ĞƚĂů͘>ĂƉĂƌŽƐĐŽƉŝĐϲϯϰ
ƐƚĂŐŝŶŐŝŶǁŽŵĞŶŽůĚĞƌƚŚĂŶϳϱǇĞĂƌƐǁŝƚŚĞĂƌůǇͲƐƚĂŐĞĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ͗ĐŽŵƉĂƌŝƐŽŶǁŝƚŚϲϯϱ
ŽƉĞŶƐƵƌŐŝĐĂůŽƉĞƌĂƚŝŽŶ͘DĞŶŽƉĂƵƐĞEzE͘ϮϳũĂŶǀϮϬϭϰ͖ϲϯϲ
ϰϯ͘ >ŽǁĞDW͕<ƵŵĂƌ^͕:ŽŚŶƐŽŶWZ͕<ĂŵĞůůĞ^͕ŚĂŵďĞƌůĂŝŶ,͕dŝůůŵĂŶŶƐd͘ZŽďŽƚŝĐϲϯϳ
ƐƵƌŐŝĐĂůŵĂŶĂŐĞŵĞŶƚŽĨĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌŝŶŽĐƚŽŐĞŶĂƌŝĂŶƐĂŶĚŶŽŶĂŐĞŶĂƌŝĂŶƐ͗ĂŶĂůǇƐŝƐŽĨϲϯϴ
ƉĞƌŝŽƉĞƌĂƚŝǀĞŽƵƚĐŽŵĞƐĂŶĚƌĞǀŝĞǁŽĨƚŚĞůŝƚĞƌĂƚƵƌĞ͘:ZŽďŽƚ^ƵƌŐ͘ϭϭũƵŝŶϮϬϭϬ͖ϰ;ϮͿ͗ϭϬϵ̻ϭϱ͘ϲϯϵ
ϰϰ͘ >ĂǀŽƵĞs͕ĞŶŐy͕>ĂƵ^͕WƌĞƐƐ:͕ďŝƚďŽů:͕'ŽƚůŝĞďZ͕ĞƚĂů͘/ŵƉĂĐƚŽĨƌŽďŽƚŝĐƐŽŶƚŚĞϲϰϬ
ŽƵƚĐŽŵĞŽĨĞůĚĞƌůǇƉĂƚŝĞŶƚƐǁŝƚŚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ͘'ǇŶĞĐŽůKŶĐŽů͘ũƵŝŶϲϰϭ
ϮϬϭϰ͖ϭϯϯ;ϯͿ͗ϱϱϲ̻ϲϮ͘ϲϰϮ
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 Ϯϰ
ϰϱ͘ dĂŚŵĂƐďŝZĂĚD͕tĂůůǁŝĞŶĞƌD͕ZŽŵ:͕^ŽŚŶ͕ŝĐŚďĂƵŵD͘>ĞĂƌŶŝŶŐĐƵƌǀĞĨŽƌϲϰϯ
ůĂƉĂƌŽƐĐŽƉŝĐƐƚĂŐŝŶŐŽĨĞĂƌůǇĂŶĚůŽĐĂůůǇĂĚǀĂŶĐĞĚĐĞƌǀŝĐĂůĂŶĚĞŶĚŽŵĞƚƌŝĂůĐĂŶĐĞƌ͘ƌĐŚϲϰϰ
'ǇŶĞĐŽůKďƐƚĞƚ͘ƐĞƉƚϮϬϭϯ͖Ϯϴϴ;ϯͿ͗ϲϯϱ̻ϰϮ͘ϲϰϱ
ϰϲ͘ ŝŶĚŽ͕ĞŵĂƌƚŝŶĞƐE͕ůĂǀŝĞŶWͲ͘ůĂƐƐŝĨŝĐĂƚŝŽŶŽĨƐƵƌŐŝĐĂůĐŽŵƉůŝĐĂƚŝŽŶƐ͗ĂŶĞǁϲϰϲ
ƉƌŽƉŽƐĂůǁŝƚŚĞǀĂůƵĂƚŝŽŶŝŶĂĐŽŚŽƌƚŽĨϲϯϯϲƉĂƚŝĞŶƚƐĂŶĚƌĞƐƵůƚƐŽĨĂƐƵƌǀĞǇ͘ŶŶ^ƵƌŐ͘ĂŽƸƚϲϰϳ
ϮϬϬϰ͖ϮϰϬ;ϮͿ͗ϮϬϱ̻ϭϯ͘ϲϰϴ
ϰϳ͘ ,ĂƵƐƉǇ:͕:ŝŵĠŶĞǌt͕ZŽƐĞŶ͕'ŽƚůŝĞďt,͕&ƵŶŐͲ<ĞĞͲ&ƵŶŐD͕WůĂŶƚĞD͘ϲϰϵ
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Table 1: Studies looking at management of endometrial cancer in elderly women  ϲϲϭ
Authors Year Study type  
Number of 
patients 
Age (years) Comparison 
Scribner et al. 36 2001 Retrospective 125  65 Laparotomy vs 
 laparoscopy 
Susini et al. 34 2004 Retrospective 171  70 Vaginal vs 
laparotomy 
Lachance et al. 19 2006 Retrospective 396  65 Age 
Vaknin et al. 35 2009 Prospective 115  70 Age 
Walker et al. 37 2009 Randomized 
study 
1682  63 Laparotomy vs 
laparoscopy 
Ghezzi et al. 38 2010 Prospective 231  70 Laparotomy vs laparoscopy 
Siesto et al. 22 2010 Prospective 108  65 Age 
Vaknin et al. 24 2010 Prospective 100  70 Age 
Lowe et al. 43 2010 Retrospective 395  80 Age 
Frey et al. 39 2011 Retrospective 129  65 Age 
Bijen et al. 40 2011 
Randomized 
study 
238  70 Laparotomy vs laparoscopy 
Perrone et al. 41 2012 Retrospective 210  70 Laparotomy vs laparoscopy 
De Marzi et al. 30 2013 Prospective 124  75 Age 
Zeng et al. 23 2013 Prospective 373  70;  80 Age 
Bogani et al. 42 2014 Retrospective 125  75 
Laparotomy vs 
laparoscopy 
Lavoue et al. 44 2014 Prospective 163  70 Laparotomy vs 
Robot 
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Table 2: Perioperative data from studies looking at surgical management of endometrial ϲϲϰ
cancer in elderly women ϲϲϱ
Study Type Operative time (min) 
Blood loss 
(ml) 
Transfusions 
(%) 
Conversion 
(%) 
Susini et al .34 Vag/Ltm  
 70 
46/115 
p=0.01 
210/400 
p=0.01 
7/5 
NS 
N/P 
Vaknin et al .35 Ltm  
 70/ < 70 
141/132 
NS 
N/P 10/4 
NS 
N/P 
Lachance et al. 19 Ltm  
 65/ <65 
176/185 
NS 
384/450 
NS 
N/P N/P 
Scribner et al. 36 Lscp / Ltm  
 65 
236/148 p=0.0001 298/336 
NS 
19.2/2.2 
p<0.0001 
22 
Bogani et al. 42 Lscp / Ltm  
 75 
120/90 
NS 
100/175 
p=0.005 
2/6 
NS 
2 
Ghezzi et al. 38 Lscp / Ltm  
 70 
N/P N/P 4.2/26.5 
p<0.05 
N/P 
Frey et al. 39 Lscp 
 65/ < 65 
229/223 
NS 
165/166 
NS 
3.2/2.7 
NS 
0/0 
Siesto et al. 22 Lscp 
 65/ < 65 
182/175 
NS 
100/100 
NS 
4.2/1.7 
NS 0/0 
Bijen et al. 40 Lscp 
 70/ < 70 
N/P N/P N/P 10.5/10.9 
NS 
Perrone et al. 41 Lscp 
 70/ < 70 
267/286 
NS 
N/P N/P 2/4 
NS 
Vaknin et al. 24 Rob 
 70/ < 70 
243/253 
NS 
83/81 
NS 
N/P N/P 
Lowe et al. 43 Rob 
 80/ < 80 
192/167 
NS 
50/50 
NS 
N/P 3.7/7 
NS 
Zeng et al. 23 Rob 
 80/ 80 to 70/< 70  
237/249/241 
NS 
88/69/78 
NS 
N/P 1/1/4 
NS 
Lavoue et al. 44 Rob/Ltm  
 70 
244.2/217.7 
p=0.09 
74.8/234 
p=0.0001 
N/P N/P 
Vag: vaginal; Ltm: Laparotomy; Lscp: Laparoscopy; Rob: Robotic; min: minutes; ml: ϲϲϲ
millilitres; % : percentages; NS: non-significant; N/P: not provided. ϲϲϳ
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Table 3: Rate of complications found in studies looking at surgical management of ϲϳϬ
endometrial cancer in elderly women ϲϳϭ
Study Type 
Perioperative 
complications 
(%) 
Postoperative 
complications 
(%) 
Overall 
complications 
Susini et al.34 Vag/Ltm 
 70 
N/P N/P 5.4/7 
NS 
Scribner et al. 36 Lscp / Ltm 
 65 
7/0 15/33 
p = 0.002 
N/P 
Bogani et al. 42 Lscp / Ltm 
 75 
3/2 
NS 
5/24 
p = 0.05 
N/P 
Ghezzi et al. 38 Lscp / Ltm 
 70 
0/5 
NS 
6.3/9.5 
NS 
N/P 
Bijen et al. 40 Lscp / Ltm 
 70 
5.3/4.3 
N/T 
23.7/17.4 
N/T 
28.9/21.7 
N/T 
Frey et al. 39 Lscp 
 65/  65 
N/P N/P 6.4/2.7 
NS 
Siesto et al. 22 Lscp 
 65/  65 
4.2/1.7 
NS 
25/23.3 
NS 
N/P 
Vaknin et al. 35 Ltm 
 70/ < 70 
N/P N/P 41.7/41.9 
NS 
DeMarzi et al. 30 Ltm 
 75/ < 75 
N/P N/P 23/9 
p = 0.032 
Vaknin et al. 24 Rob 
 70/ < 70 
0/2 
NS 
12/5* 
NS 
N/P 
Lowe et al. 43 Rob 
 80/ < 80 
7.4/5.1 
NS 
33/13 
p = 0.022 
N/P 
Zeng et al. 23 Rob 
 80/ 80 to 70/< 70  
3/0/0.5 
NS 
10/1/0* 
p = 0.0035 
N/P 
Lavoue et al. 44 Rob/Ltm 
 70 
N/P 17/60** 
p < 0.0001 
N/P 
Vag: vaginal; Ltm: Laparotomy; Lscp: Laparoscopy; Rob: Robotic; NS: non-significant; N/T: ϲϳϮ
not tested; N/P: not provided; * grade I/II or ** grade III/IV complications of the Clavien ϲϳϯ
Dindo classification  ϲϳϰ
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Table 4: Length of hospital stay in studies looking at surgical management of endometrial ϲϳϴ
cancer in elderly women ϲϳϵ
Study Type Length of hospital 
stay (d) 
p value
Susini et al. 34 Vag/Ltm    70 6/10 0.05 
Scribner et al. 36 Lscp / Ltm     65 3/5.6 p < 0.0001 
Bogani et al. 48 Lscp / Ltm    75 2/6 p < 0.0001 
Ghezzi et al. 38 Lscp / Ltm    70 2.5/7 p < 0.05 
Frey et al. 39 Lscp    65/  65 2.9/1.7 NS 
Siesto et al. 22 Lscp    65/  65 2/2 NS 
Perrone et al. 41 Lscp    70/ < 70 3.6/3.6 NS 
Vaknin et al. 35 Ltm    70/ < 70 5.4/4.9 NS 
DeMarzi et al. 30 Ltm    80/ < 80 9.3/7.7 p = 0.036 
Vaknin et al. 24 Rob    70/ < 70 2/1 NS 
Lowe et al. 43 Rob    80/ < 80 1/1 NS 
Zeng et al. 23 Rob    80/ 80 to 70/< 70 2/1/1 NS 
Lavoue et al. 44 Rob/Ltm  70 3.1/8 p < 0.0001 
Vag: vaginal; Lscp: Laparoscopy; Ltm: Laparotomy; Rob: Robotic; d: days; NS: non-ϲϴϬ
significant. ϲϴϭ
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Table 5: Mean number of lymph nodes removed in studies looking at surgical management of ϲϴϴ
endometrial cancer in elderly women ϲϴϵ
Study Type No of pelvic lymph nodes 
No of lombo-
aortic lymph 
nodes 
Total No of 
lymph 
nodes 
p value
Scribner et al. 36 Lscp / Ltm     65 17.8/19.1 6.6/5.2 N/P NS 
Bogani et al. 42 Lscp / Ltm    75 N/P N/P 14/13 NS 
Frey et al. 39 Lscp   65/  65 N/P N/P 19.2/17.3 NS 
Siesto et al. 22 Lscp    65/  65 N/P N/P 18/18 NS 
Perrone et al. 41 Lscp   70/ < 70 N/P N/P 15.2/18.6 NS 
Vaknin et al. 35 Ltm    70/ < 70 N/P N/P 4/10.4 <0.001 
Lachance et al. 19 Ltm    65/ <65 N/P N/P 17.9/14.7 NS 
Vaknin et al. 24 Rob    70/ < 70 N/P N/P 11/13 0.006 
Lowe et al. 43 Rob    80/ < 80 N/P N/P 16/16 NS 
Zeng et al. 23 Rob    80/80 to 70/< 70  N/P N/P 9.7/10.3/11.8 NS 
Lavoue et al. 44 Rob /Ltm   70 8.8/8.4 N/P 10.3/9.7 NS 
Lscp: Laparoscopy; Ltm: Laparotomy; Rob: Robotic; No: number; NS: non-significant; N/P: ϲϵϬ
not provided. ϲϵϭ
ϲϵϮ
